VKTX Stock Flat After 22% Weight Loss Win: Why Viking Therapeutics VK2735 Data Got Ignored
Viking Therapeutics reported 22% weight loss versus placebo at week 33 for obesity candidate VK2735 with no plateau observed. Despite the durability signal, VKTX stock...
